Five Pharma Giants Unveil Next-Generation Obesity Drug Plans at ADA Annual Conference in New Orleans

According to the American Diabetes Association's annual scientific conference held recently in New Orleans, five major pharmaceutical companies—Eli Lilly, Novo Nordisk, Amgen, Zealand Pharma, and Structure Therapeutics—presented their future obesity drug development strategies to physicians and investors. The firms are aiming to build on existing treatments including Wegovy, Zepbound, Wegovy oral tablet, and Foundayo.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments